ONCAlert | 2018 Gastrointestinal Cancers Symposium

Renal Cell Carcinoma MORE >>

The first-in-class glutaminase inhibitor CB-839 showed encouraging activity and tolerability when combined with everolimus and cabozantinib in heavily pretreated patients with metastatic renal cell carcinoma, according to results from a phase I study presented in a poster session at the 2018 Genitourinary Cancers Symposium in San Francisco, California.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.